Lower Circulating C1q/TNF-Related Protein-3 (CTRP3) Levels Are Associated with Obesity: A Cross-Sectional Study.
Lower Circulating C1q/TNF-Related Protein-3 (CTRP3) Levels Are Associated with Obesity: A Cross-Sectional Study.
复制标题
DOI：
10.1371/journal.pone.0133955
复制
发表时间：
2015
期刊：
影响因子：
3.7
通讯作者：
Wong GW
中科院分区：
文献类型：
--
作者：
Wolf RM;Steele KE;Peterson LA;Magnuson TH;Schweitzer MA;Wong GW
C1 q/TNF相关蛋白-3（CTRP 3）是一种新型脂肪因子，可降低血糖水平，减少肝脏甘油三酯合成，并在饮食诱导的肥胖小鼠模型中保护肝脏脂肪变性。我们假设，较高的循环血清CTRP 3水平将与瘦体重指数（BMI）和人类更有利的代谢特征相关。本研究的目的是研究瘦个体与肥胖个体的CTRP 3水平。这是一项对肥胖（n=44）和瘦对照患者（n=60）的横断面研究。测定所有患者的空腹代谢参数，并通过ELISA测定血清CTRP 3水平。瘦型组的BMI为21.9 ± 0.2 kg/m2，肥胖组为45.2 ± 1.1 kg/m2。我们发现与瘦型组相比，肥胖个体中CTRP 3的循环水平显著较低（405 ± 8.3对436± 6.7ng/mL，p=0.004）。血清CTRP 3水平与BMI（p=0.001）和甘油三酯（p<0.001）呈负相关，与性别（p<0.01）、种族（p=0.05）、HDL-胆固醇（p<0.01）和脂联素（p<0.01）显著相关。我们发现BMI（p<0.01）、性别（p<0.01）和种族（p<0.05）在多元回归分析中控制年龄时是CTRP 3水平的重要预测因素。CTRP 3是一种有益的脂肪因子，其循环水平在肥胖个体中显著较低。肥胖导致脂肪因子产生失调，包括CTRP 3的下调。较低的CTRP 3水平可能有助于与肥胖相关的代谢紊乱的病理生理学。通过新疗法优化CTRP 3水平可能会改善肥胖及其合并症。
C1q/TNF-related protein-3 (CTRP3) is a novel adipokine that lowers blood glucose levels, reduces liver triglyceride synthesis, and is protective against hepatic steatosis in diet-induced obese mouse models. We hypothesized that higher circulating serum levels of CTRP3 would be associated with a lean body mass index (BMI) and a more favorable metabolic profile in humans. The aim of this study was to investigate CTRP3 levels in lean individuals compared to obese individuals. This was a cross-sectional study of obese (n=44) and lean control patients (n=60). Fasting metabolic parameters were measured in all patients and serum CTRP3 levels were measured by ELISA. BMI of the lean group was 21.9 ± 0.2 kg/m2 and obese group was 45.2 ± 1.1 kg/m2. We found significantly lower circulating levels of CTRP3 in obese individuals (405 ± 8.3 vs. 436± 6.7ng/mL, p=0.004) compared to the lean group. Serum CTRP3 levels were inversely correlated with BMI (p=0.001), and triglycerides (p<0.001), and significantly associated with gender (p<0.01), ethnicity (p=0.05), HDL-cholesterol (p<0.01), and adiponectin (p<0.01). We found BMI (p<0.01), gender (p<0.01), and ethnicity (p<0.05) to be significant predictors of CTRP3 levels when controlling for age in multiple regression analysis. CTRP3 is a beneficial adipokine whose circulating levels are significantly lower in obese individuals. Obesity causes dysregulation in adipokine production, including the down-regulation of CTRP3. Lower CTRP3 levels may contribute to the pathophysiology of metabolic disorders associated with obesity. Optimizing CTRP3 levels through novel therapies may improve obesity and its comorbidities.